Clomiphene Citrate
Clomid · Serophene · Milophene · clomiphene
Last updated
At a glance
Overview
Clomid has been the backbone of male post-cycle therapy for thirty years, and for good reason — it's cheap, oral, well-studied, and reliably restarts a suppressed HPG axis when you run it correctly. A 2022 meta-analysis of nearly 1,700 men put the average total testosterone bump at roughly 2.6-fold over baseline, with adverse events described as rare.
"CC treatment was associated with a significant increase in total testosterone level versus baseline (mean increase 2.6-fold, 95% CI 2.0–3.1; 19 studies, 1642 men) while adverse events were rare." — Huijben et al., Andrology (2022)
Physique-focused users reach for clomid in three distinct contexts: classic 4-week PCT after a suppressive cycle (usually 50/50/25/25 mg/day, often alongside nolvadex), monotherapy at 12.5–25 mg daily or EOD as a fertility-preserving alternative to TRT, and fertility restarts after long AAS exposure, typically stacked with HCG. What makes it earn its spot over a pure anti-estrogen is mechanism — clomid stimulates GnRH pulsatility upstream, so LH, FSH, intratesticular testosterone, and spermatogenesis all come back online together, rather than just papering over low E2 at the breast.
The caveats are real but manageable: clomid is a racemic mix, and the long-half-life zuclomiphene isomer accumulates over weeks of dosing, driving the well-known mood and visual side effects that give clomid its reputation. Understanding that isomer split is the key to using it well — and knowing when to switch to enclomiphene instead. Below we'll cover the full dosing ladder, PCT vs. monotherapy protocols, how to stack it with nolvadex and HCG, how to manage E2 and moods without crushing recovery, and how clomid compares to enclomiphene and tamoxifen for your specific use case.
How Clomiphene Citrate works
Clomiphene citrate is a first-generation selective estrogen receptor modulator (SERM) from the triphenylethylene family — the same chemical scaffold as tamoxifen. It's a racemic mix of two geometric isomers that behave very differently in the body: enclomiphene (the antagonist that does the work) and zuclomiphene (a weak agonist with a multi-week half-life that drives most of the sides). Understanding the split is the whole game.
Hypothalamic ER Blockade and the LH/FSH Surge#
The core mechanism: clomid competitively blocks estrogen receptor α (ERα) at the hypothalamus. Normally, circulating estradiol binds ERα on kisspeptin and GnRH neurons and tells them to slow down — classic negative feedback. Clomid occupies those receptors without activating them, so the hypothalamus "thinks" estrogen is low and ramps GnRH pulse frequency. The pituitary follows with elevated LH (driving Leydig-cell testosterone synthesis) and FSH (driving Sertoli-cell spermatogenesis).
This is what makes clomid categorically different from exogenous testosterone: TRT suppresses the axis, clomid stimulates it. That's why it's the canonical PCT tool and why it preserves testicular volume and fertility instead of shutting them down.
"CC treatment was associated with a significant increase in total testosterone level versus baseline (mean increase 2.6-fold, 95% CI 2.0–3.1; 19 studies, 1642 men) while adverse events were rare." — Huijben, M. et al. Andrology, 2022
The Enclomiphene vs Zuclomiphene Split#
Racemic clomid is roughly 62% enclomiphene / 38% zuclomiphene, and the two isomers do nearly opposite things:
- Enclomiphene (trans) — a relatively clean ER antagonist, half-life ~10 hours, cleared in days. This isomer is responsible for essentially all of the desired LH/FSH rise.
- Zuclomiphene (cis) — a weak ER agonist with a terminal half-life measured in weeks. It accumulates with daily dosing and is the isomer implicated in mood sides, visual disturbance, and adverse tissue effects in preclinical work.
"Zuclomiphene produced significantly lower serum testosterone with adverse effects on histology of Leydig cells and seminal vesicles compared to enclomiphene." — Ganesan, K. et al. BJU International, 2016
"Plasma concentrations of zuclomiphene were measurable 21 days after a single dose, showing a markedly prolonged half-life compared with enclomiphene." — Ghobadi, C. et al. Journal of Clinical Pharmacology, 2009
Practical takeaway: short PCT blocks (≤4 weeks) don't give Zu time to accumulate to problematic levels. Long monotherapy runs do — which is why users who bridge on clomid for months frequently swap to isolated enclomiphene once mood or libido starts sliding.
Tissue-Selective Agonism (Why E2 Goes UP on Clomid)#
SERMs aren't blanket anti-estrogens — they're tissue-selective. Clomid antagonizes ER at the hypothalamus but behaves as a partial agonist at the liver, bone, and (via Zu) breast tissue. Combined with the fact that the LH surge drives more testosterone, and more testosterone means more substrate for aromatase, the predictable result is that estradiol rises alongside testosterone on clomid.
In Guay's cohort running 25 mg/day, total T climbed from 248 → 610 ng/dL while E2 went from 21 → 35 pg/mL — both moving together.
"After 4–6 weeks of clomiphene citrate 25 mg daily, mean total testosterone increased from 248±93 to 610±241 ng/dL (P<0.001), and estradiol from 21±7 to 35±13 pg/mL (P<0.001)." — Guay, A.T. et al. International Journal of Impotence Research, 2006
This is why you don't stack an AI into PCT reflexively. Some E2 is necessary for the LH response, libido, joint feel, and mood recovery. Crushing it with anastrozole during a restart is a classic way to end PCT with worse symptoms than you started with. Only pull the AI trigger if bloods confirm symptomatically high E2.
Breast and Uterine ER Antagonism (The Anti-Gyno Effect)#
At breast tissue, clomid acts as an ER antagonist — weakly, but enough to blunt estrogen-driven ductal proliferation. This is where its anti-gynecomastia utility comes from, though tamoxifen is the stronger and more targeted SERM for active gyno lumps. Clomid's mixed profile (weak Zu agonism at breast) is the reason nolvadex is preferred when you're actually chasing down puffy nipples or palpable tissue mid-cycle.
Downstream: Leydig and Sertoli Reactivation#
The elevated LH and FSH have to find functional testicular tissue to do anything. In a short, mild cycle, Leydig cells are quiescent but intact, and clomid wakes them up within days. In a long, deeply suppressive run (year-long blasts, 19-nor-heavy cycles, or anyone who ran AAS without HCG), the testes have atrophied and the Leydig cells down-regulate their LH receptors — a flood of LH from clomid lands on a desensitized receptor pool and the restart stalls.
This is the mechanistic case for HCG priming before SERM PCT: 1,500–2,500 IU twice weekly for 2–3 weeks directly stimulates Leydig cells (HCG is an LH analog), restoring testicular size and LH-receptor density so that when clomid ramps endogenous LH, there's something for it to act on. Long-term follow-up data show that once the axis is restarted, 50 mg every other day maintains eugonadal testosterone indefinitely in men who want an ongoing alternative to TRT.
"Long-term follow-up (mean 19 months) indicated that clomiphene citrate at 50 mg every other day maintained eugonadal testosterone concentrations and was well tolerated." — Moskovic, D.J. et al. BJU International, 2012
The practical chain of events — hypothalamic ER blockade → GnRH pulses → LH/FSH surge → Leydig/Sertoli reactivation → endogenous T and spermatogenesis — is exactly the sequence a suppressed axis needs to run in reverse. Clomid's job is to push the first domino; the rest is biology.
Protocol
| Level | Dose | Frequency | Notes |
|---|---|---|---|
| Low | 12.5–25 mg | Once daily | Documented entry-level range |
| Mid | 25–50 mg | Once daily | Most commonly studied range |
| High | 50–100 mg | Once daily | Standard 4-week PCT: 50/50/25/25 mg/day. Monotherapy / bridge: 12.5–25 mg daily or 25 mg EOD. Time-of-day doesn't matter much — consistency does. |
Cycle length & outcomes
Documented cycle
4–6 weeks
Plateau after
6 wks
Cycle Length & Protocol Design#
Clomid is a short-duration tool. Unlike anabolics where you're chasing accumulating gains, clomid's job is to kick the HPG axis back online — then get out before zuclomiphene accumulation starts causing more problems than it solves. The long-acting Zu isomer builds to steady-state over roughly 4–6 weeks of daily dosing, which is exactly why standard PCT blocks cap at four weeks and monotherapy users drop to EOD schedules.
"Plasma concentrations of zuclomiphene were measurable 21 days after a single dose, showing a markedly prolonged half-life compared with enclomiphene." — Ghobadi et al., J Clin Pharmacol (2009)
Cycle Length by Goal#
| Goal | Cycle Length | Dose Protocol |
|---|---|---|
| Standard PCT (test-only or moderate cycle) | 4 weeks | 50/50/25/25 mg/day |
| Heavy/long-cycle PCT | 4 weeks | 50/50/50/25 mg/day + nolvadex 20/20/10/10 |
| SARM PCT (LGD, RAD-140, ostarine >8wk) | 4 weeks | 25 mg/day |
| Fertility restart (post-AAS) | 8–12 weeks | 25 mg/day + HCG 1,500 IU 2×/wk |
| Monotherapy / "mini-TRT" bridge | Ongoing | 12.5–25 mg daily or 25 mg EOD |
| Post-SARM light recovery | 3–4 weeks | 12.5–25 mg/day |
Onset & Timing#
LH and FSH respond fast — within 3–5 days of the first dose you'll see measurable pituitary output. Total testosterone typically rises meaningfully by week 2 and approaches the ~2.6× baseline response by week 4–6.
"After 4–6 weeks of clomiphene citrate 25 mg daily, mean total testosterone increased from 248±93 to 610±241 ng/dL (P<0.001), and estradiol from 21±7 to 35±13 pg/mL (P<0.001)." — Guay et al., Int J Impot Res (2006)
"CC treatment was associated with a significant increase in total testosterone level versus baseline (mean increase 2.6-fold, 95% CI 2.0–3.1; 19 studies, 1642 men) while adverse events were rare." — Huijben et al., Andrology (2022)
PCT start timing — this is where most failed PCTs fail:
- Test E/C (long esters): start ~14 days after last pin
- Test P / NPP (short esters): start ~3 days after last pin
- Oral-only cycle: start 24–48h after last tab
- SARMs: 24–48h after last dose
Starting before exogenous androgen clears means you're antagonizing estrogen at a hypothalamus that's still getting suppressed by circulating T. You waste the SERM block.
No Taper, No Load#
There is no loading phase and no taper. The 50/50/25/25 structure isn't a taper in the pharmacological sense — it's a front-load to get LH moving, then a maintenance dose while the axis stabilizes. You can run flat 25 mg/day for four weeks and get a similar result; the front-loaded version is just the community default because heavier cycles benefit from the early push.
Stopping cold-turkey after four weeks is fine. Zu will clear over the following weeks on its own.
Monotherapy: Different Rules#
If you're running clomid as an ongoing TRT alternative rather than a 4-week PCT block, switch to EOD or every-third-day dosing to minimize Zu accumulation.
"Long-term follow-up (mean 19 months) indicated that clomiphene citrate at 50 mg every other day maintained eugonadal testosterone concentrations and was well tolerated." — Moskovic et al., BJU Int (2012)
If mood sides emerge past month 2–3 on monotherapy, that's the Zu talking — swap to enclomiphene 12.5–25 mg/day, which clears in hours and doesn't accumulate.
"Zuclomiphene produced significantly lower serum testosterone with adverse effects on histology of Leydig cells and seminal vesicles compared to enclomiphene." — Ganesan et al., BJU Int (2016)
Bloodwork Cadence#
| Timepoint | Panel |
|---|---|
| Baseline (pre-cycle) | Total T, free T, E2 sensitive, LH, FSH, SHBG, CBC, CMP, lipids |
| Week 4 of PCT (last day) | LH, FSH, total T, E2 sensitive |
| Week 8 (4 weeks post-PCT) | Full repeat — confirms recovery held |
| Monotherapy: 6–8 weeks in | Total T, free T, E2, LH, SHBG |
The week-8 post-PCT draw is the one that actually matters. Plenty of guys finish PCT with solid numbers only to crash two weeks later when the SERM clears — a proper confirmation draw at +4 weeks tells you whether the axis is genuinely self-sustaining or whether you need an HCG bridge and another round.
If week-4 LH is flat despite a full clomid protocol, suspect the product before suspecting your axis — underdosed UGL liquid clomid is a known failure mode. Pharma tabs or a reputable compounding pharmacy remove that variable entirely.
Risks & mistakes
Common (most users)#
- Emotional lability / "clomid moods" — irritability, tearfulness, low-grade anxiety. Driven largely by zuclomiphene accumulation over weeks of daily dosing. Mitigation: keep PCT to 4 weeks, drop to 25 mg once week 3 hits, or switch to enclomiphene if you're running monotherapy past 6 weeks.
- Hot flashes — mild, transient, classic SERM effect. Mitigation: usually resolves within 2–3 weeks; split the dose AM/PM if bothersome.
- Headache — dose-related. Mitigation: hydration, back off to 25 mg/day if persistent.
- Nausea — mild, usually first week. Mitigation: take with food.
- Nipple sensitivity / mild puffiness — paradoxical, from the E2 rise that accompanies the T rise. Mitigation: do NOT panic-dose an AI. Add or increase nolvadex (10–20 mg/day) which blocks ER at the breast directly.
- Libido dip mid-PCT — extremely common around weeks 2–3, usually because E2 is climbing faster than T is catching up, or because the user crushed E2 with an AI. Mitigation: ride it out; pull bloods at week 4 before intervening.
Uncommon (dose-dependent or individual)#
- Visual disturbances — floaters, light-streaking, afterimages, shimmering at the edge of vision. Almost always dose- and duration-dependent (≥50 mg/day extended runs). Action: stop immediately — do not push through. Usually reversible but persistent cases exist.
- Estradiol overshoot — more T → more aromatization, plus clomid is weakly pro-estrogenic in peripheral tissues. Action: check sensitive E2 at week 3–4. If symptomatically high (water, mood, nips), add nolvadex rather than an AI.
- Gynecomastia (paradoxical) — rare but documented, driven by zuclomiphene's weak ER agonism in susceptible users. Action: swap to nolvadex-only PCT or enclomiphene.
- Lipid shifts — modest LDL bump, HDL dip on extended runs. Bloodwork: lipid panel at baseline and if running >8 weeks.
- Mild transaminase elevation — uncommon, usually subclinical. Bloodwork: CMP at week 4–6 of extended runs.
- Ovarian-style pelvic discomfort in women using off-label — not relevant to male PCT.
"CC treatment was associated with a significant increase in total testosterone level versus baseline (mean increase 2.6-fold, 95% CI 2.0–3.1; 19 studies, 1642 men) while adverse events were rare." — Huijben et al., Andrology (2022)
Rare but serious#
- Persistent visual disturbance — scotomata or posterior vitreous changes that don't resolve after stopping. Very rare but the reason the "stop at first visual side" rule is non-negotiable.
- Thromboembolism (DVT/PE) — class effect of triphenylethylene SERMs. Risk compounds if you're already high-hematocrit from a cycle. Warning signs: unilateral calf swelling/pain, sudden shortness of breath, chest pain. Mitigation: donate blood before PCT if Hct >52%; hydrate aggressively.
- Severe mood decompensation — frank depression, suicidal ideation in susceptible users on prolonged high-dose runs. Action: stop and switch to nolvadex or enclomiphene. Guys with a personal/family history of major depression should default to enclomiphene from the start.
- Hepatotoxicity — very rare, usually reversible on discontinuation.
"Zuclomiphene produced significantly lower serum testosterone with adverse effects on histology of Leydig cells and seminal vesicles compared to enclomiphene." — Ganesan et al., BJU International (2016)
"Plasma concentrations of zuclomiphene were measurable 21 days after a single dose, showing a markedly prolonged half-life compared with enclomiphene." — Ghobadi et al., Journal of Clinical Pharmacology (2009)
This is the pharmacological basis for every "clomid moods" anecdote — Zu builds to steady state over 4–6 weeks and lingers for weeks after you stop. Short PCT blocks (≤4 weeks) largely dodge it. Extended monotherapy is where enclomiphene earns its premium.
Hard contraindications#
- Active thromboembolic disease, or personal history of DVT / PE / stroke — do not run clomid. Use nolvadex-only PCT if a SERM is required.
- Pre-existing liver disease — contraindicated.
- Known hormone-sensitive tumor — contraindicated.
- Visual disturbance on therapy — stop immediately and do not re-challenge. This is the one side effect where "push through" is the wrong answer.
- Partner actively pregnant or attempting pregnancy with her taking clomid — female clomid use is Category X; do not share tabs, do not let a pregnant partner handle crushed tablets.
- Uncontrolled hyperlipidemia — stabilize lipids first; clomid can worsen them modestly.
Gender and PCT considerations#
Men (the focus here): clomid is the PCT — no ancillary SERM is needed for the SERM itself. Post-PCT bloodwork at 4 weeks after the last tab confirms the axis restarted; flat LH at that point means either the product was underdosed, suppression was deeper than the protocol handled (needs HCG bridge + longer SERM run), or you started PCT before exogenous androgens cleared.
Fertility-focused users: if conception is on the near-term horizon, the clean play is enclomiphene 12.5–25 mg/day rather than racemic clomid — same LH/FSH stimulation, none of the Zu accumulation, and the cleaner spermatogenesis data.
Women: off-label ovulation-induction dosing (50 mg days 5–9 of menstrual cycle) is a completely different protocol and out of scope for PED use. Women running AAS do not use clomid for PCT — they stop the compound and let the axis recover.
"Long-term follow-up (mean 19 months) indicated that clomiphene citrate at 50 mg every other day maintained eugonadal testosterone concentrations and was well tolerated." — Moskovic et al., BJU International (2012)
The headline on clomid safety: in the published literature, at clinically relevant doses (12.5–50 mg/day or 50 mg EOD), adverse events are uncommon and mostly mild. The community pitfalls — mood, vision, paradoxical gyno — almost all trace back to running too high a dose for too long. Keep PCT blocks to 4 weeks, reserve ≥50 mg/day for the first two weeks only, pull bloods, and switch to enclomiphene the moment you're looking at a run longer than 6 weeks.
Stack & combine
Multipliers applied when these compounds run together. Values > 1 indicate a bonus on that axis. Tap a partner to expand the mechanism.
| Partner | Type | Lean | Fat loss | Recovery |
|---|---|---|---|---|
| synergistic | ×1.10 | ×1.00 | ×1.18 |
FAQ — Clomiphene Citrate
Where to buy
Swiss Chems
Affiliate link — we may earn a commission at no cost to you.
- Buy Clomiphene, 1500mg (25mg/capsule) - SwissChems - Buy Best Quality Peptides, SARMS OnlineBuy Clomiphene Citrate
NextChems
Affiliate link — we may earn a commission at no cost to you.
- Clomid (Clomifene, Clomiphene), 25 mg - 60 capsules - Next ChemsBuy Clomiphene Citrate
Research & citations
5 studies cited on this page.
Conclusion
Clomid (clomiphene citrate) remains a foundational tool for post-cycle therapy and HPTA restart, reliably boosting LH/FSH and natural testosterone when run on the right protocol. Used smartly, it restores endocrine function with a solid track record and manageable sides.
Key takeaways:
- Standard PCT: 50/50/25/25 mg/day over 4 weeks; monotherapy: 12.5–25 mg/day or every other day
- Best stacked with tamoxifen (nolvadex) for dual-SERM coverage, HCG if suppression was prolonged
- Oral tablets or research liquid both effective—dose consistency trumps route
- Start PCT only after compounds clear; premature timing is a top self-sabotage
- Limit continuous clomid runs to 4–6 weeks at ≤50 mg/day to dodge zuclomiphene-driven mood/vision sides
- If sides persist or for long-term use, enclomiphene is the cleaner isomer upgrade
When used within established dose/duration windows, clomid is a proven backbone for restoring endogenous function—and one every advanced PED user should have in their toolkit.